{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:15:08Z","timestamp":1788052508599,"version":"build-2784847793"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119188","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:11:00Z","timestamp":1785481860000},"page":"119188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery, synthesis, and biological evaluation of N,N\u2032-diacyl-m-phenylenediamine derivatives as novel PCSK9 small-molecule inhibitors"],"prefix":"10.1016","volume":"318","author":[{"given":"Li Rui","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruize","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song Hui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9288-0652","authenticated-orcid":false,"given":"Li Ping","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.ejmech.2026.119188_bib1","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119188_bib2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119188_bib3","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119188_bib4","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1073\/pnas.051630598","article-title":"An orchestrated gene expression component of neuronal programmed cell death revealed by cDNA array analysis","volume":"98","author":"Chiang","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2026.119188_bib5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3389\/fnins.2020.00609","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) in the brain and relevance for neuropsychiatric disorders","volume":"14","author":"O'Connell","year":"2020","journal-title":"Front. Neurosci."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119188_bib6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/hep.22354","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration","volume":"48","author":"Zaid","year":"2008","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119188_bib7","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119188_bib8","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119188_bib9","doi-asserted-by":"crossref","first-page":"914","DOI":"10.5114\/aoms.2017.65239","article-title":"PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade","volume":"13","author":"Jaworski","year":"2017","journal-title":"Arch. Med. Sci."},{"issue":"18","key":"10.1016\/j.ejmech.2026.119188_bib10","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1073\/pnas.0402133101","article-title":"Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype","volume":"101","author":"Maxwell","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119188_bib11","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1600-0854.2007.00562.x","article-title":"The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR","volume":"8","author":"Nassoury","year":"2007","journal-title":"Traffic"},{"issue":"7","key":"10.1016\/j.ejmech.2026.119188_bib12","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1194\/jlr.M700071-JLR200","article-title":"Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis","volume":"48","author":"Qian","year":"2007","journal-title":"J. Lipid Res."},{"issue":"Suppl","key":"10.1016\/j.ejmech.2026.119188_bib13","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejmech.2026.119188_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173114","article-title":"Statins and PCSK9 inhibitors: a new lipid-lowering therapy","volume":"878","author":"Gallego-Colon","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119188_bib15","series-title":"Report on the Deliberation Results: Repatha (evolocumab [genetical recombination]); Tokyo","article-title":"Pharmaceuticals and medical devices","year":"2016"},{"key":"10.1016\/j.ejmech.2026.119188_bib16","series-title":"Repatha (Evolocumab): Epar\u2014Public Assessment Report","year":"2015"},{"issue":"19","key":"10.1016\/j.ejmech.2026.119188_bib17","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.3390\/cells11192972","article-title":"PCSK9 inhibition: from current advances to evolving future","volume":"11","author":"Liu","year":"2022","journal-title":"Cells"},{"issue":"16","key":"10.1016\/j.ejmech.2026.119188_bib18","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119188_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2001882","article-title":"Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain","volume":"15","author":"Lintner","year":"2017","journal-title":"PLoS Biol."},{"issue":"Suppl_3","key":"10.1016\/j.ejmech.2026.119188_bib20","doi-asserted-by":"crossref","first-page":"A12579","DOI":"10.1161\/circ.142.suppl_3.12579","article-title":"Abstract 12579: CVI-LM001, a first-in-class novel oral PCSK9 modulator, lowers plasma Ldl-c and reduces circulating PCSK9 in preclinical animal models and in hyperlipidemic human subjects","volume":"142","author":"Liu","year":"2020","journal-title":"Circulation"},{"issue":"41","key":"10.1016\/j.ejmech.2026.119188_bib21","doi-asserted-by":"crossref","first-page":"9736","DOI":"10.1039\/C6OB01642A","article-title":"Disrupting the PCSK9\/LDLR protein-protein interaction by an imidazole-based minimalist peptidomimetic","volume":"14","author":"Stucchi","year":"2016","journal-title":"Org. Biomol. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119188_bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.chembiol.2019.10.002","article-title":"From screening to targeted degradation: strategies for the discovery and optimization of small molecule ligands for PCSK9","volume":"27","author":"Petrilli","year":"2020","journal-title":"Cell Chem. Biol."},{"issue":"11 Pt 1","key":"10.1016\/j.ejmech.2026.119188_bib23","first-page":"3712","article-title":"Phase 1 clinical investigation of 4-(9-Acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative","volume":"38","author":"Legha","year":"1978","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119188_bib24","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1002\/jps.2600640933","article-title":"Relationship of in vitro hydrolysis of 17\u2010Chloroacetylajmaline and 17\u2010Acetylajmaline in different animal species","volume":"64","author":"Fanelli","year":"1975","journal-title":"J. Pharmaceut. Sci."},{"issue":"30","key":"10.1016\/j.ejmech.2026.119188_bib25","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1021\/acs.jafc.7b02657","article-title":"New aromatic compounds from the fruiting body of Sparassis crispa (Wulf.) and their inhibitory activities on proprotein convertase subtilisin\/kexin type 9 mRNA expression","volume":"65","author":"Bang","year":"2017","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2026.119188_bib26","series-title":"Anti-Proprotein Convertase Subtilisin Kexin Type 9 (anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and\/or Prevention of Cardiovascular Diseases","author":"Salaheldin","year":"2014"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119188_bib27","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3349\/ymj.2015.56.5.1251","article-title":"In silico screening of chemical libraries to develop inhibitors that hamper the interaction of PCSK9 with the LDL receptor","volume":"56","author":"Min","year":"2015","journal-title":"Yonsei Med. J."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119188_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115344","article-title":"A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove","volume":"28","author":"Evison","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119188_bib29","series-title":"Preparation of Imidazolylbenzene Derivatives and Analogs for Use as PCSK9 Inhibitors","author":"Treutlein","year":"2018"},{"issue":"13","key":"10.1016\/j.ejmech.2026.119188_bib30","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1021\/acs.jmedchem.9b00402","article-title":"Computationally driven structure optimization, synthesis, and biological evaluation of imidazole-based proprotein convertase subtilisin\/kexin 9 (PCSK9) inhibitors","volume":"62","author":"Lammi","year":"2019","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.ejmech.2026.119188_bib31","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1016\/j.bmc.2010.06.034","article-title":"Identification of a potent and noncytotoxic inhibitor of melanin production","volume":"18","author":"Hwang","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119188_bib32","series-title":"E.g., as Antidiabetics, and Pharmaceutical Compositions","article-title":"Methylene amides, particularly [(arylmethyl)amino](oxo)acetic acids, useful as modulators, and especially inhibitors, of protein tyrosine phosphatases (PTPs), and their preparation, uses","author":"Swinnen","year":"2003"},{"issue":"12","key":"10.1016\/j.ejmech.2026.119188_bib33","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1021\/ar000033j","article-title":"Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models","volume":"33","author":"Kollman","year":"2000","journal-title":"Acc. Chem. Res."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119188_bib34","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/minf.201100135","article-title":"Free energy calculations by the molecular mechanics poisson-boltzmann surface area method","volume":"31","author":"Homeyer","year":"2012","journal-title":"Mol. Inf."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119188_bib35","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/s41401-024-01305-9","article-title":"A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis","volume":"45","author":"Wang","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119188_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100293","article-title":"Small-molecule inhibitor of PCSK9 with significant cholesterol-lowering properties in vivo","volume":"63","author":"Suchowerska","year":"2022","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119188_bib37","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/6985808","article-title":"PCSK9-D374Y suppresses hepatocyte migration through downregulating free cholesterol efflux rate and activity of extracellular signal-regulated kinase","volume":"2023","author":"Huang","year":"2023","journal-title":"Anal. Cell. Pathol."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119188_bib38","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J. Med. Chem."},{"issue":"1762","key":"10.1016\/j.ejmech.2026.119188_bib39","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/978-1-4939-7756-7_14","article-title":"Prediction and-optimization ofPharmacokinetic and toxicity properties of the ligand","author":"Pires","year":"2018","journal-title":"Methods Mol. Biol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:21:44Z","timestamp":1788049304000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426006331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":39,"alternative-id":["S0223523426006331"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119188","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery, synthesis, and biological evaluation of N,N\u2032-diacyl-m-phenylenediamine derivatives as novel PCSK9 small-molecule inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119188","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119188"}}